PEPTIDES & ANTIBODIES - Peptides in Antibody & Peptide Drug Conjugates July 7, 2014

Archana Gangakhedkar, MS, and Jyothi Thundimadathil, PhD, indicate peptide-based linkers are promising counterparts in ADCs, providing tumor-specific cleavable and stable circulating linkers, and a new emerging class of PDCs is proving to be useful toward a broad spectrum of indications when compared to ADCs.

Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3 July 6, 2022

THERAPEUTIC PEPTIDES - Continuous Manufacturing of Peptides Could Speed Up Development, Reduce Costs & Improve Quality March 31, 2020

Jens Bukrinski, PhD, MSc, says the high-quality, high-process consistency between manufacturing runs and the in-line PAT analytics of the μLOT platform will enable unprecedented robustness of the manufacturing process, significantly retiring the risk of failure to supply due to non-scalability of the manufacturing process.

ANTIBODY DRUG CONJUGATES - Expansion of Approved Indications Backs 25% Increase in Global Market October 1, 2018

Laurie L. Sullivan and Shalini Shahani Dewan, MS, believe technological advancements, the rising incidence of cancer, and an increasing demand for biologic therapies are all factors driving growth in the global ADC market.

INTRABODY DELIVERY - The Feldan Shuttle Technology: A Peptide-Based Method to Deliver Antibodies January 8, 2018

Thomas Del’Guidice, PhD, Nancy Messier, PhD, and David Guay, PhD, present the Feldan Shuttle technology, a peptide-based delivery method that could provide efficient and safe intrabody delivery in mammalian cells.

Ajinomoto Althea, Inc. Announces Issuance of New US Patent for Manufacturing of Crystal Monoclonal Antibodies May 17, 2016

ANTIBODY DRUG CONJUGATES - ADC Development Using SMARTag(TM) Technology April 1, 2014

Robyn M. Barfield, PhD, and David Rabuka, PhD, say that despite challenges, there has been progress in advancing complex compounds through clinical trials and successfully treating patients, and these bioconjugate compounds include a subset of molecules known as ADCs.

pSivida Announces Evaluation Agreement for Protein/Antibody Delivery System July 30, 2012

SPECIAL FEATURE - Excipients: Advanced Biologics Require Innovative Excipient Science March 29, 2024

Contributor Cindy H. Dubin speaks with several leading companies to discuss novel and functional excipients being developed, the role they will play in reformulations and new formulations, and their versatility in drug delivery.

DRUG DELIVERY PLATFORM - VitalDose® EVA Implants for Systemic & Local Delivery of Therapeutics March 28, 2024

Cyonna Holmes, PhD, Karen Chen, MS, and Brian Duke explain how systemic delivery approaches that leverage continuous dosing can address adherence issues and improve drug effectiveness while minimizing adverse reactions, and how a localized delivery approach can minimize total drug exposure, reduce off-target toxicities, and overcome targeting issues.

Abzena Partners With FDA on MAPPs Assay Publication December 20, 2023

Abzena has recently co-authored a publication with the US FDA demonstrating the potential of the MHC Associated Peptide Proteomics (MAPPs) assay as an important method to interrogate immunogenicity risk….

Ocean Biomedical, Inc. Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day August 1, 2023

On World Lung Cancer Day, Ocean Biomedical, Inc. is sharing details of its multi-pronged Lung Cancer Program built on novel immunotherapy discoveries by Scientific Co-founder Dr. Jack A. Elias. He and his team have revealed that Chitinase 3-like-1 (CHi3L1) is a master regulator that inhibits….

Evonik Launches Next-Generation Peptide for Biopharma Applications May 31, 2023

Evonik now offers cQrex® KC, a performance-boosting peptide for cell culture media used in the manufacture of biological drugs. The new peptide enables cell culture process developers….

Ocean Biomedical, Inc. Announces Patent Award for Novel Cancer Immunotherapy Treatment Granted for Prostate Cancer, Colon Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma & Lung Cancer May 23, 2023

Bhami Research Laboratory & Catalent Enter Licensing Agreement for Technology to Deliver High-Concentration Biologics Subcutaneously March 16, 2023

PLATFORM TECHNOLOGY - Versamune®: A New Generation of Cancer Immunotherapies October 26, 2022

Dr. Joe Dervan says the unique ability of Versamune® to modulate and enhance numerous critical steps required for an e­ffective clinically relevant immune response and to be combined with targeted antigens found on tumor cells o­ffers several exciting opportunities to treat a variety of cancers.

EXTRACELLULAR VESICLES - Engineering Extracellular Vesicles to Create Next-Generation Therapeutics October 3, 2022

David Lowe, PhD, Justin Hean, PhD, Dave Carter, PhD, and Antonin de Fougerolles, PhD, say EVs exhibit key properties that make them extremely attractive as therapeutics, particularly their safety profile and potential for low immunogenicity. In order to effectively unlock this potential, some key challenges remain, such as the development of EV product manufacture and characterization methodologies and rapid pharmacokinetics.

Wheeler Bio Announces President & Chief Operating Officer  September 26, 2022

Wheeler Bio, a new CDMO specializing in the cell line development, process development, and small batch clinical production of antibodies, has announced the appointment of….

Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates August 1, 2022

Vaxxinity, Inc. recently presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau protein for Alzheimer’s disease (AD) during a poster session at the….

Apellis Expands R&D Collaboration With Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain June 22, 2022

Apellis Pharmaceuticals, Inc. and Affilogic recently announced the companies have expanded their research and development (R&D) collaboration, which was initially formed in 2018, to include the development of Nanofitins….

Pace Analytical Life Sciences

Abzena